India's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With potential growth to $22-25 billion by 2035, the industry aims to compete globally, but currently faces delays and higher costs compared to Chinese counterparts.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bH8MIAN
via IFTTT
No comments:
Post a Comment